$LNTH has a lot to offer for long as a maturing company. It develops (and sells) diagnostic imaging agents and radiopharmaceuticals. These are used for diagnosis and treatment of cancer. 

Since 2020 it's in collab with Ibex (AI healthtech) to develop an AI-powered system for improving prostate cancer diagnoses accuracy. They also collaborated with PYLARIFY AI, to improve accuracy of echocardiography diagnoses. 

FY 2022 results saw a 119.9% increase in revenue to US$935. They also recently acquired Progenics, a company developing AI-powered imaging agents for cancer diagnosis. 

I'll do some further DD through fundamental fact checking (company, growth, management etc), but I see some potential here and wanted to share. 

Let me know what you think. 

https://investor.lantheus.com/